Vijay Pande's Shift to Smaller AI-Native Fund Signals Evolving Biotech VC Strategy
Vijay Pande, formerly leading a $4 billion biotech practice at a16z, has launched VZVC, a new AI-native fund focused on 'smaller bets,' signaling a strategic pivot in venture capital's approach to biotech innovation.